Results 61 to 70 of about 62,601,321 (172)

Torsade de pointes in a patient with acute prolonged QT syndrome and poorly controlled diabetes during sevoflurane anaesthesia

open access: yes, 2010
The article describes the case of a torsade de pointes resulting from acute prolonged QT interval prolongation in a diabetic patient anesthetized with sevoflurane. Torsade de pointes is a type of ventricular tachycardia. The patient, who was undergoing a
van Wijk, R.   +13 more
core   +1 more source

Prevalence and Characteristics of Potential QT‐Interval‐Prolonging Drug–Drug Interactions in Patients Receiving Oral Anticancer Drugs

open access: yesPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 12, December 2026.
ABSTRACT Background Patients with cancer are at increased risk of QT interval prolongation because of polypharmacy and concomitant use of QT‐prolonging medications. Drug–drug interactions (DDIs) may further increase this risk. Outpatient electrocardiogram (ECG) monitoring appears to be underused among patients receiving oral anticancer drugs (OADs ...
Fatimah Alhurayri   +10 more
wiley   +1 more source

Torsadogenic risk of antipsychotics : combining adverse event reports with drug utilization data across Europe [PDF]

open access: yes, 2013
Antipsychotics (APs) have been associated with risk of torsade de Pointes (TdP). This has important public health implications. Therefore, (a) we exploited the public FDA Adverse Event Reporting System (FAERS) to characterize their torsadogenic profile; (
Barbui, Corrado   +72 more
core   +2 more sources

Signal detection and characterisation of a novel drug–drug interaction between methadone and a synthetic cannabinoid receptor agonist

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 23, Page 6787-6800, December 2026.
Background and Purpose Little is known about how synthetic cannabinoid receptor agonist (SCRA) co‐use with other psychoactive substances may exacerbate risk of death. This study aimed to characterise the polypharmacy of deaths where SCRAs were detected at post‐mortem, investigate the cardiotoxicity of SCRAs and probe their inhibition of human ether‐a ...
Kirsten L. Rock   +9 more
wiley   +1 more source

Advances in New Approach Methodologies at FDA's Division of Applied Regulatory Science

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1250-1254, November 2026.
New Approach Methodologies (NAMs) represent a paradigm shift in drug development and regulatory science, offering human‐relevant alternatives to traditional preclinical models. This mini‐review highlights recent advances in NAM development, validation, and regulatory application from FDA's Division of Applied Regulatory Science (DARS).
Ksenia Blinova   +9 more
wiley   +1 more source

Acquired Long QT Syndrome and Torsade de Pointes Associated with HIV Infection

open access: yesCase Reports in Medicine, 2010
Here, we report the case of an HIV infected patient that was treated for pneumonia with a macrolid antibiotic. The patient experienced a prolongation of the already pathologic QTc interval resulting in repeated torsades de pointes necessitating CPR and ...
Alexander Shimabukuro-Vornhagen   +7 more
doaj   +1 more source

In Silico Clinical Trials in Drug Development: Virtual Patients, Applications, and Regulatory Convergence

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1181-1194, November 2026.
Conventional clinical trials remain the benchmark for evaluating therapeutic safety and efficacy, yet they are constrained by escalating costs, withdrawal over the extended follow‐up periods, recruitment difficulties, ethical limits, and a restricted ability to characterize heterogeneous populations.
Maximilian Balmus   +7 more
wiley   +1 more source

Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3‐ITD–Positive AML

open access: yesCancer Science, Volume 117, Issue 11, Page 3108-3120, November 2026.
ABSTRACT Quizartinib is a FMS‐like tyrosine kinase 3 (FLT3) inhibitor indicated for FLT3 internal tandem duplication (FLT3‐ITD)–positive acute myeloid leukemia (AML). We aimed to evaluate quizartinib resistance mechanisms, in addition to efficacy and safety outcomes, in patients with relapsed or refractory FLT3‐ITD–positive AML.
Yuichiro Semba   +21 more
wiley   +1 more source

Torsade de pointes. Mechanisms and Management.

open access: yes, 1994
Torsade de pointes is a polymorphic ventricular tachycardia showing a peculiar electrocardiographic pattern characterised by a continuous twisting in QRS axis around an imaginary baseline.
SCHWARTZ, PETER   +2 more
core  

E-4031-induced torsade de pointes is potentiated by hmr1556 or atx-ii but is not predicted by action potential short-term variability or triangulation

open access: yes, 2008
This paper examines E-4031-induced torsade de pointes is potentiated by hmr1556 or atx-ii but is not predicted by action potential short-term variability or ...
Kane, K.A., Michael, G., Coker, S.J.
core   +3 more sources

Home - About - Disclaimer - Privacy